Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson's disease.



http://www.ncbi.nlm.nih.gov/pubmed/23483627


Abstract


BACKGROUND:

We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan.

METHODS:

A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.

RESULTS:

The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P = .003) and istradefylline 40 mg/day (-0.96 hours, P = .003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).

CONCLUSIONS:

Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa